Why a U.S. Chitosan Producing Company is Gaining Investor Attention
How one chitosan producer's vertical integration and patent strategy set it apart in a $6.3 billion market
About three years ago I had just finished up an undergraduate degree in chemistry, and after that I spent about a year working in the research and development area of material science, specifically in the nonwoven industry. After that short period of time of working in that particular space, I found an inspiration to apply to law school, and I recently finished my first year.
Throughout my life I’ve always enjoyed writing, and currently I’ve found myself with an interest in how science intersects in a business sense. I wanted to write about something current happening in the nonwoven industry, and through my search I came across Tidal Vision, a private chitosan producing company founded in 2015.
What caught my attention initially was that they were pulling investor interest. Tidal Vision operates through a vertical integration strategy that, as of 2026, is unique to the chitosan producing market, meaning they control both the extraction and formulation of chitosan rather than relying on third parties for either step.
In February 2025, Tidal Vision closed a $140M Series B financing round, backed by investors including Cambridge Companies SPG, Eni Next, and Milliken & Company. CEO Craig Kasberg said the company had “already demonstrated it’s possible to make our biomolecular solutions outcompete.”
For those who don’t know, Chitosan is a biopolymer formed from the shell of crustaceans, used in the pharmaceutical, medical, cosmetics, and biotech industries. The method of deriving chitosan from chitin, consisting of deacetylation and reduced temperatures, was patented in 1980 by Quintin P. Peniston and Edwin L. Johnson. This patent has since expired, which highlights the shift in the market toward finding novelty beyond the initial derivation and pushing companies into specialized products or bulk production.
Tidal Vision formulates specialized products but goes beyond that. The company also controls both the extraction and formulation of the chitosan product by way of vertical integration. Vertical integration involves a company taking control over at least two steps in the value chain to streamline the operational process, increasing market share and potential buying power while aiming to limit inefficiencies. There are potentials to achieve higher profit margins, however, a drawback is the high initial cost required, which could prevent or delay a profitable integration. Tidal Vision is cited as the only vertically integrated chitosan producer in the world, a feature that may have added lure to past funding and promoted growth.
In addition to vertical integration, they pursue a strategy of creating a lower cost biopolymer solution compared to the synthetic chemicals it aims to displace. This is part of the company’s three-layered business strategy, described as an environmentally friendly way to extract chitosan from the seafood industry. The CEO has noted that the main industry competition comes from displacing these non-biodegradable chemicals. In a 2022 New York Rural Water Association article, the CEO further describes this green chemistry method, which allows non-hazardous byproducts to be recycled and turned into fertilizer. This brings a wide range of chitosan molecular weights, leading to higher efficacy in water treatment at half the cost. This lower cost is precisely what allows the chemical displacement to occur.
Furthermore, Tidal Vision focuses on specialty products that are application specific, rather than low-cost bulk-produced commodity chitosan, prompting high margins and industrial chemical displacement. This specialty product market may align with the company’s budding IP strategy. Tidal Vision holds, as of 2026, five total patent documents, with three currently pending. One thing to note: two of the patent documents, although filed on May 8, 2023, are labeled as inactive. Being labeled inactive could be a potential drawback, as the patents can no longer be enforced, though the three pending still signal future proprietary development of specialty products.
Given that Tidal Vision is one company of many in the broader market, it’s worth looking at the chitosan market as a whole. As of 2026, the chitosan market is estimated at $6.30 billion, projected to grow to $11.30 billion by 2031 at a CAGR of 12.38%. This represents a 0.29% decline from the broader 2026 biotech CAGR of 12.67%. However, the growing need for environmental compliance and high margin specialty products could further contribute to growth in future years.
The market spans many industries. In the food industry, chitosan derivatives can reduce fasting glucose and serve as a prebiotic supplement. Industrial chitosan use has expanded to address residue caps, prompting pulp and paper mills to trial chitosan alternatives to other chemicals. Chitosan derivatives are also able to remove heavy metals, aiding water treatment regulation. The pharmaceutical sector is utilizing chitosan nanoparticles for drug delivery innovation, and textile applications include military hemostatic dressings. By contrast, Tidal Vision focuses on serving mainly the textile, water treatment, and agriculture industries.
Looking at companies that make up the market, Primex ehf and G.T.C Bio Corporation are listed as two of the five chitosan industry leaders. Primex, located in Iceland, uses wild shrimp shells to bulk produce and deliver products to industries such as cosmetics, biomedical, food, and agriculture, acting as a bulk biomaterials supplier with medical-grade, high-purity offerings. G.T.C. Bio Corporation is located in Shandong Province, China, and manufactures chitosan and chitosan derivatives across agriculture, chemicals, health and medicine, and more, including various derivative types like chitosan oligosaccharide and chitosan lactate. This suggests a model built around bulk produced chitosan derivatives.
Because these companies are private, there are no public financial statements or regulatory filings, such as EBITDA disclosures; this analysis relies on business structure and third-party market reports.
Geographically, the chitosan market landscape is complex, with multiple regions competing in different segments. Europe is cited as the fastest growing market, with a CAGR of 14.51%, attributed to wastewater mandates, trauma centers standardizing chitosan dressings, and Germany funding municipal trials, among other factors. North America, capturing 25.13% of the chitosan market in 2025, is the largest market, driven by low contaminant shells, attractive pharmaceutical prospects, and early battlefield use of chitosan hemostats. The Asia-Pacific region, however, holds 68% of global volume share, producing chitosan for fertilizer, cosmetics, pharmaceuticals, and more.
Even though these companies are cited as industry leaders across a vast set of markets, Tidal Vision is nonetheless gaining leverage of its own through its focus on specialty, application-specific products rather than low-cost bulk commodity chitosan. This could give way to a broad range of growth, including possible international expansion.
Tidal Vision is carving out its own lane with application-specific formulations that can substitute for existing industrial chemicals. They are more than a bulk chitosan producer; it is a vertically integrated, IP-driven specialty chemicals business operating in a diverse set of industries. The company exhibits clear signals of momentum in the chitosan industry, and time will tell if that growth holds.
Disclaimer
The content published in Nummus is for informational and educational purposes only and does not constitute financial, investment, legal, or professional advice. The views expressed in this article are those of the author and do not represent the views of Nummus or its editors. Readers should not rely on any content published in Nummus as a basis for making financial or investment decisions and are encouraged to consult a qualified financial advisor before doing so.
 |
|